BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Real-time Estimate Cboe BZX Other stock markets 02:07:40 24/01/2026 am IST			5-day change	1st Jan Change
56.54 ^USD	-1.12%		+3.59%	-4.85%

21/01	When America Starts to Feel Like a Risky Asset
20/01	Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84	MT

Transcript : BioMarin Pharmaceutical Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 10

Published on 11/18/2025 at 05:05 pm IST - Modified on 11/18/2025 at 07:20 pm IST

S&P Capital IQ

Presenter Speech
Akash Tewari (Analysts)

Day 2 of our London Healthcare Conference. Great to see everyone. Always really appreciative of the attendance. My name is Akash Tewari. I'm a pharma and

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about BioMarin Pharmaceutical Inc.

21/01	When America Starts to Feel Like a Risky Asset
20/01	Canaccord Genuity Upgrades BioMarin Pharmaceutical to Buy From Hold, Adjusts Price Target to $98 From $84	MT
20/01	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
20/01	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
14/01	BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says	MT
13/01	BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down	MT
13/01	Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FY - SEC filing	RE
13/01	BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer	MT
13/01	BioMarin Pharmaceutical Inc. Appoints Arpit Davé as Executive Vice President and Chief Digital and Information Officer	CI
13/01	BioMarin Pharmaceutical Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
08/01	Veeva Systems, BioMarin Pharmaceutical Enter Long-Term Partnership	MT
08/01	Veeva and Biomarin form long-term strategic partnership	RE
22/12	Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating	MT
22/12	BioMarin Pharmaceutical Inc. Announces its Decision to Discontinue Development of BMN349	CI
20/12	Health Care Up Amid Deal Activity -- Health Care Roundup	DJ
20/12	Sector Update: Health Care Stocks Rise Late Afternoon	MT
20/12	Sector Update: Health Care Stocks Higher Friday Afternoon	MT
19/12	Sector Update: Health Care	MT
19/12	Top Midday Gainers	MT
19/12	Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals	MT
19/12	BioMarin Pharmaceutical Inc. submitted a non-binding indication of interest to acquire Amicus Therapeutics, Inc. from The Vanguard Group, Inc., Wellington Management Group LLP, BlackRock, Inc., William Blair Investment Management, LLC, and others for $4.7 billion.	CI
19/12	Amicus Therapeutics, Inc., BioMarin Pharmaceutical Inc. - M&A Call
19/12	BioMarin Pharmaceutical to Acquire Amicus Therapeutics in $4.8 Billion Deal	MT
19/12	BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 Billion; Shares Jump	MT
19/12	Amicus to pay Biomarin Pharmaceutical $175 million merger termination fee	RE